Myelodysplastic Syndromes — Higher-Risk (IPSS-R high / very high; includes MDS-EB) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-ANKRD26-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-20 \| pending_clinical_signoff
Diseases	`DIS-MDS-HR`
Sources	`SRC-ELN-AML-2022` `SRC-ESMO-MDS-2021` `SRC-NCCN-AML-2025`

Notes

STUB — Wave P confirmed-carrier surveillance pathway (ANKRD26 THC2). Two-Clinical-Co-Lead signoff queued. Sibling — IND-ANKRD26-CARRIER-INTENSIFIED (aggressive plan_track).

Used By

Indication

IND-ANKRD26-CARRIER-INTENSIFIED - IND-ANKRD26-CARRIER-INTENSIFIED

Red flag

RF-ANKRD26-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in ANKRD26 (Thrombocytopenia 2,...